News

The posters demonstrate the capability of opti-ox technology to create any human cell.

bit.bio wins biotech of the year for the second time and CEO of the year for Mark Kotter.

The new Huntington’s disease human cell model is built with opti-ox reprogrammed glutamatergic neurons.

bit.bio appoints accomplished biotechnology executive and drug developer Kathryn Corzo as Chief Operating Officer.

The pledge is part of our mission to code cells for novel cures and to be a purpose led company.

Funding raised to accelerate and expand cell therapy pipeline.

Three world leaders in science and entrepreneurship appointed to bit.bio's Board of Directors.

This is the first supply of consistent, scalable, human muscle cells, providing transformative new models for drug discovery.